June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
NCX 470, a nitric oxide (NO)-donating prostaglandin analog, elicits sustained IOP-lowering and modifies aqueous humor dynamic in non-human primates
Author Affiliations & Notes
  • Elena Bastia
    Nicox Research Institute, Italy
  • Carol B Toris
    University of Nebraska Omaha, Omaha, Nebraska, United States
  • Shan Fan
    University of Nebraska Omaha, Omaha, Nebraska, United States
  • stefania brambilla
    Nicox Research Institute, Italy
  • Corinna Galli
    Nicox Research Institute, Italy
  • José L Boyer
    Nicox Ophthalmics Inc, North Carolina, United States
  • Francesco Impagnatiello
    Nicox Research Institute, Italy
  • Footnotes
    Commercial Relationships   Elena Bastia Nicox Research Institute, Code E (Employment); Carol Toris Nicox Research Institute, Code F (Financial Support); Shan Fan None; stefania brambilla Nicox Research Institute, Code E (Employment); Corinna Galli Nicox Research Institute, Code E (Employment); José Boyer NIcox Ophthalmic Inc, Code E (Employment); Francesco Impagnatiello Nicox Research Institute, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2839 – A0362. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elena Bastia, Carol B Toris, Shan Fan, stefania brambilla, Corinna Galli, José L Boyer, Francesco Impagnatiello; NCX 470, a nitric oxide (NO)-donating prostaglandin analog, elicits sustained IOP-lowering and modifies aqueous humor dynamic in non-human primates. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2839 – A0362.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To explore the effects of NCX 470, a nitric oxide (NO)-donating prostaglandin analog, on aqueous humor dynamics in ocular normotensive non-human primates.

Methods : Ocular hypotensive activity after topical dosing with NCX 470 ophthalmic solution 0.1% or its vehicle was tested in ocular normotensive non-human primates (n=6-12) using a randomized, investigator-masked, parallel-group design. Baseline intraocular pressure (IOP) was measured (pneumatonometer, Reichert), after which animals were treated twice daily (10:00AM & 4:00PM) for 3 consecutive days and once (AM dose) on day 4 (experimental day). On day 4 IOP measurements were taken at 90, 180 and 300min after the AM dose. Additionally, on day 4, animals were dosed topically with 10% fluorescein and fluorophotometric scans (Fluorotron Master, OcuMetrics) of the cornea and anterior chamber were taken at 45min intervals throughout the experimental period to address changes in aqueous inflow, outflow facility and uveoscleral outflow.

Results : Baseline IOP was similar between groups (23.7±0.9 and 23.3±1.1mmHg in NCX 470 0.1% and vehicle, respectively). On day 4, the IOP reductions with NCX 470 were greater than those with vehicle and were sustained throughout the entire experimental period [Change From Baseline (CFB), NCX 470CFB =7.8±0.7, 5.5±0.9 and 6.5±1.0mmHg and VEHCFB=4.8±0.9, 2.9±0.9 and 3.5±1.4mmHg at 90, 180 and 300min post-dosing, respectively]. In addition, NCX 470 increased outflow facility (0.64±0.17 and 0.37±0.09µl/min/mmHg for NCX 470 and vehicle, respectively) and uveoscleral outflow (2.58±0.61 and 1.24±0.26µl/min for NCX 470 and vehicle, respectively) leaving unaltered aqueous inflow (1.93±0.31 and 2.03±0.22µl/min for NCX 470 and vehicle, respectively).

Conclusions : NCX 470 increased uveoscleral outflow and outflow facility in ocular normotensive non-human primates suggesting that changes in both pathways contribute to the IOP-lowering effect of this compound.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×